



Catalog Number:	MO15093	Host:	Mouse
Product Type:	Protein G purified IgG _{2B} . Clone: 81401	Species Reactivity:	Rat
Immunogen Sequence:	Hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, NS0-derived, recombinant rat GDNF family receptor alpha 1 (rrGFR α -1) extracellular domain.	Format:	Liquid 1mg/ml Solution in phosphate-buffered saline (PBS) with 5% Trehlose
Applications:	Immunohistochemistry -25 μ g/mL Western Blot-1 - 2 μ g/mL Dilutions listed as a recommendation. Optimal dilution should be determined by investigator.		
Storage:	Antibody can be aliquotted and stored frozen at -20° C to -70° C in a manual defrost freezer for six months without detectable loss of activity. The antibody can be stored at 2° - 8° C for 1 month without detectable loss of activity. <i>Avoid repeated freeze-thaw cycles.</i>		

Application Notes

Specificity

Less than 0.25% cross-reactivity was observed with rhIGF-I R, rhIGFBP-1, rhIGFBP-2, rhIGFBP-4, rhIGFBP-5, and rhIGFBP-6.

Western Blot

This antibody can be used at 1 - 2 μ g/mL with the appropriate secondary reagents to detect human IGFBP-3. Using a colorimetric detection system, the detection limit for rhIGFBP-3 is approximately 25 ng/lane under non-reducing and reducing conditions. Chemiluminescent detection with WesternGlo Chemiluminescent Detection Substrate will increase sensitivity by 5 to 50 fold.

Immunohistochemistry

This antibody was used at a concentration of 25 μ g/mL with appropriate secondary reagents to detect IGFBP-3 in paraffin-embedded human placenta tissue sections.

FOR RESEARCH USE ONLY

NEUROMICS' REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RSKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.

10/07v2

www.neuromics.com

Neuromics Antibodies • 5325 West 74th Street, Suite 8 • Edina, MN 55439
phone 866-350-1500 • fax 612-677-3976 • e-mail pshuster@neuromics1.com

Figure 1




Figure 2




Figure 1

Human MIP-1 α chemoattracts BaF/3-hCCR5 cells. The number of cells that have migrated through to the lower chamber are quantitated using Resazurin staining. The ED₅₀ for this effect is typically 0.003 - 0.01 $\mu\text{g/mL}$.

Figure 2

To measure the ability of the antibody to block rhMIP-1 α mediated chemotaxis of BaF/3 hCCR5 cells, rhMIP-1 α at 40 ng/mL was added to the lower compartment of a 96-well chemotaxis chamber (NeuroProbe, Cabin John, MD). The chemotaxis chamber was then assembled using a PVP-free polycarbonate filter (5 micron pore size). Serial dilutions of the antibody (at the concentrations indicated) and 0.25×10^6 cells/well were added to the top wells of the chamber. After incubation for 3 hours at 37° C in a 5% CO₂ humidified incubator, the chamber was disassembled and the cells that migrated through to the lower chamber were transferred to a working plate and quantitated using Resazurin Fluorescence. As shown in Figure 2, the ND₅₀ for this lot of antibody is approximately 5 - 20 $\mu\text{g/mL}$.

FOR RESEARCH USE ONLY

NEUROMICS' REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RSKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.

10/07v2

www.neuromics.com

Neuromics Antibodies • 5325 West 74th Street, Suite 8 • Edina, MN 55439
phone 866-350-1500 • fax 612-677-3976 • e-mail pshuster@neuromics1.com